AdVantage Therapeutics wins $2.5M NIH grant to advance Alzheimer’s drug

AdVantage Therapeutics said it has been awarded a Phase II Small Business Innovation Research (SBIR) grant of $2.5 million from the National Institute on Aging (NIA) to support its Alzheimer’s drug candidate, AD04, according to the company. The company claims this non-dilutive funding will help advance AD04 toward clinical validation and regulatory progress. AdVantage notes […] The post AdVantage Therapeutics wins $2.5M NIH grant to advance Alzheimer’s drug appeared first on Longevity.Technology.